Potential Alzheimer’s disease drug targets identified through microglial biology research

References

• World Health Organisation (WHO). Global action plan on the public health response to dementia 2017 – 2025. Geneva World Health Organ. 2017;52:1–27.
   Google Scholar
• Abubakar MB, Sanusi KO, Ugusman A, et al. Alzheimer’s disease: an update and insights into pathophysiology. Front Aging Neurosci. 2022;14:1–16. doi: 10.3389/fnagi.2022.742408
   Web of Science ®Google Scholar
• Sierra A, Paolicelli RC, Kettenmann H. Cien años de microglía: milestones in a century of microglial research. Trends Neurosci. 2019;42(11):778–792. doi: 10.1016/j.tins.2019.09.004
   PubMed Web of Science ®Google Scholar
• Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci. 2008;28(33):8354–8360. doi: 10.1523/JNEUROSCI.0616-08.2008
   PubMed Web of Science ®Google Scholar
• Hodges AK, Piers TM, Collier D, et al. Pathways linking Alzheimer’s disease risk genes expressed highly in microglia. Neuroimmunol Neuroinflam. 2021;8:245–268. doi: 10.20517/2347-8659.2020.60
   Google Scholar
• Karch CM, Jeng AT, Nowotny P, et al. Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PloS One. 2012;7(11):e50976. doi: 10.1371/journal.pone.0050976
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Q, Lin JR, et al. Deep post-GWAS analysis identifies potential risk genes and risk variants for Alzheimer’s disease, providing new insights into its disease mechanisms. Sci Rep. 2021;11(1):20511. doi: 10.1038/s41598-021-99352-3
   PubMed Web of Science ®Google Scholar
• Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–172. doi: 10.1038/s41582-020-00435-y
   PubMed Web of Science ®Google Scholar
• de Oliveira J, Kucharska E, Garcez ML, et al. Inflammatory cascade in Alzheimer’s disease pathogenesis: a review of experimental findings. Cells. 2021;10(10):2581. doi: 10.3390/cells10102581
   PubMed Web of Science ®Google Scholar
• Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2018;4(1):575–590. doi: 10.1016/j.trci.2018.06.014
   PubMedGoogle Scholar
• Chai YL, Lee JH, Chong JR, et al. Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer’s disease but not Lewy body dementias. J Neuroinflammation. 2023;20(1):111. doi: 10.1186/s12974-023-02789-8
   PubMed Web of Science ®Google Scholar
• Baik SH, Kang S, Lee W, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer’s disease. Cell Metab. 2019;30(3):493–507.e6. doi: 10.1016/j.cmet.2019.06.005
   PubMed Web of Science ®Google Scholar
• Meng JX, Zhang Y, Saman D, et al. Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses. Nat Commun. 2022;13(1):2692. doi: 10.1038/s41467-022-30461-x
   PubMed Web of Science ®Google Scholar
• Sierra A, Gottfried-Blackmore AC, McEwen BS, et al. Microglia derived from aging mice exhibit an altered inflammatory profile. Glia. 2007;55(4):412–424. doi: 10.1002/glia.20468
   PubMed Web of Science ®Google Scholar
• Bickford PC, Flowers A, Grimmig, et al. Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases. Exp Gerontol. 2017;94:4–8. doi: 10.1016/j.exger.2017.01.027
   PubMed Web of Science ®Google Scholar
• Holtman IR, Raj DD, Miller JA, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun. 2015;3(1):31. doi: 10.1186/s40478-015-0203-5
   PubMedGoogle Scholar
• Edler MK, Mhatre-Winters I, Richardson JR. Microglia in aging and Alzheimer’s disease: a comparative species review. Cells. 2021;10(5):1138. doi: 10.3390/cells10051138
   PubMed Web of Science ®Google Scholar
• Xiao S-Y, Liu Y-J, Lu W, et al. Possible neuropathology of sleep disturbance linking to Alzheimer’s disease: astrocytic and microglial roles. Front Cell Neurosci. 2022;16:875138. doi: 10.3389/fncel.2022.875138
   PubMed Web of Science ®Google Scholar
• Liu S, Meng Y, Wang N, et al. Disturbance of REM sleep exacerbates microglial activation in APP/PS1 mice. Neurobiol Learn Mem. 2023;200:107737. doi: 10.1016/j.nlm.2023.107737
   PubMed Web of Science ®Google Scholar
• Guillot-Sestier MV, Araiz AR, Mela V, et al. Microglial metabolism is a pivotal factor in sexual dimorphism in Alzheimer’s disease. Commun Biol. 2021;4(1):711. doi: 10.1038/s42003-021-02259-y
   PubMed Web of Science ®Google Scholar
• Whiten DR, Brownjohn PW, Moore S, et al. Tumour necrosis factor induces increased production of extracellular amyloid-β-and α-synuclein-containing aggregates by human Alzheimer’s disease neurons. Brain Commun. 2020;2(2):fcaa146. doi: 10.1093/braincomms/fcaa146
   PubMedGoogle Scholar
• Salvadores N, Moreno-Gonzalez I, Gamez N, et al. Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease. Acta Neuropathol Commun. 2022;10(1):31. doi: 10.1186/s40478-022-01332-9
   PubMed Web of Science ®Google Scholar
• Jayaraman A, Htike TT, James R, et al. TNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer’s disease hippocampus. Acta Neuropathol Commun. 2021;9(1):159. doi: 10.1186/s40478-021-01264-w
   PubMed Web of Science ®Google Scholar
• Fu P, Peng F. CSF TNF-α levels were associated with conversion from mild cognitive impairment to dementia. PLoS One. 2022;17(10):e0274503. doi: 10.1371/journal.pone.0274503
   PubMed Web of Science ®Google Scholar
• Zhao A, Li Y, Deng Y. TNF receptors are associated with tau pathology and conversion to Alzheimer’s dementia in subjects with mild cognitive impairment. Neurosci Lett. 2020;738:135392. doi: 10.1016/j.neulet.2020.135392
   PubMed Web of Science ®Google Scholar
• Shi J-H, Sun S-C. Tumor necrosis factor receptor-associated factor regulation of Nuclear factor κB and mitogen-activated protein kinase pathways. Front Immunol. 2018;9:1849. doi: 10.3389/fimmu.2018.01849
   PubMed Web of Science ®Google Scholar
• Ofengeim D, Mazzitelli S, Ito Y, et al. RIPK1 mediates a disease-associated microglial response in alzheimer’s disease. Proc Natl Acad Sci USA. 2017;114(41):E8788–97. doi: 10.1073/pnas.1714175114
   PubMed Web of Science ®Google Scholar
• Steeland S, Gorlé N, Vandendriessche C, et al. Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer’s disease. EMBO Mol Med. 2018;10(4):e8300. doi: 10.15252/emmm.201708300
   PubMed Web of Science ®Google Scholar
• Ou W, Yang J, Simanauskaite J, et al. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy. J Neuroinflammation. 2021;18(1):312. doi: 10.1186/s12974-021-02332-7
   PubMed Web of Science ®Google Scholar
• Liang T, Zhang Y, Wu S, et al. The role of NLRP3 inflammasome in Alzheimer’s disease and potential therapeutic targets. Front Pharmacol. 2022;13:845185. doi: 10.3389/fphar.2022.845185
   PubMed Web of Science ®Google Scholar
• Xu Y, Yang Y, Chen X, et al. NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors. Transl Neurodegener. 2023;12(1):49. doi: 10.1186/s40035-023-00381-x
   PubMed Web of Science ®Google Scholar
• Chen X, Wang Y. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol. 2008;9(8):857–865. doi: 10.1038/ni.1636
   PubMed Web of Science ®Google Scholar
• Valenzuela-Arzeta IE, Soto-Rojas LO, Flores-Martinez YM, et al. LPS triggers acute neuroinflammation and parkinsonism involving NLRP3 inflammasome pathway and mitochondrial CI dysfunction in the rat. Int J Mol Sci. 2023;24(5):4628. doi: 10.3390/ijms24054628
   PubMed Web of Science ®Google Scholar
• Ahmed ME, Iyer S, Thangavel R, et al. Co-localization of Glia maturation factor with NLRP3 inflammasome and autophagosome markers in human Alzheimer’s disease brain. J Alzheimer’s Dis. 2017;60(3):1143–1160. doi: 10.3233/JAD-170634
   PubMed Web of Science ®Google Scholar
• Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–678. doi: 10.1038/nature11729
   PubMed Web of Science ®Google Scholar
• Sharma B, Satija G, Madan A, et al. Role of NLRP3 inflammasome and its inhibitors as emerging therapeutic drug candidate for Alzheimer’s disease: a review of mechanism of activation, regulation, and inhibition. Inflammation. 2023;46(1):56–87. doi: 10.1007/s10753-022-01730-0
   PubMed Web of Science ®Google Scholar
• Han J, Chitu V, Stanley ER, et al. Inhibition of colony stimulating factor‑1 receptor (CSF‑1r) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges. Cell Mol Life Sci. 2022;79(4):219. doi: 10.1007/s00018-022-04225-1
   PubMed Web of Science ®Google Scholar
• Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584–1593. doi: 10.1038/nn.4132
   PubMed Web of Science ®Google Scholar
• Shi Y, Manis M, Long J, et al. Microglia drive ApoE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546–2561. doi: 10.1084/jem.20190980
   PubMed Web of Science ®Google Scholar
• Spangenberg EE, Lee RJ, Najafi AR, et al. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-β pathology. Brain. 2016;139(4):1265–1281. doi: 10.1093/brain/aww016
   PubMedGoogle Scholar
• Casali BT, Macpherson KP, Reed-Geaghan EG, et al. Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis. 2020;142:104956. doi: 10.1016/j.nbd.2020.104956
   PubMed Web of Science ®Google Scholar
• Olmos-Alonso A, Schetters STT, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 2016;139(3):891–907. doi: 10.1093/brain/awv379
   PubMedGoogle Scholar
• Sun E, Motolani A, Campos L, et al. The pivotal role of NF-κB in the pathogenesis and therapeutics of Alzheimer’s disease. Int J Mol Sci. 2022;23(16):8972. doi: 10.3390/ijms23168972
   PubMed Web of Science ®Google Scholar
• Wang H, Li Y, Ryder JW, et al. Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model. Mol Neurodegener. 2018;13(1):65. doi: 10.1186/s13024-018-0296-y
   PubMedGoogle Scholar
• Lindsay A, Hickman D, Srinivasan M. A nuclear factor-kappa B inhibiting peptide suppresses innate immune receptors and gliosis in a transgenic mouse model of Alzheimer’s disease. Biomed Pharmacother. 2021;138:111405. doi: 10.1016/j.biopha.2021.111405
   PubMed Web of Science ®Google Scholar
• Wang C, Fan L, Khawaja RR, et al. Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy. Nat Commun. 2022;13(1):1969. doi: 10.1038/s41467-022-29552-6
   PubMed Web of Science ®Google Scholar
• Rusek M, Smith J, El-Khatib K, et al. The role of the JAK/STAT signaling pathway in the pathogenesis of Alzheimer’s disease: new potential treatment target. Int J Mol Sci. 2023;24(1):864. doi: 10.3390/ijms24010864
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. doi: 10.1038/s41392-021-00791-1
   PubMed Web of Science ®Google Scholar
• Przanowski P, Dabrowski M, Ellert-Miklaszewska A, et al. The signal transducers STAT1 and STAT3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia. J Mol Med. 2014;92(3):239–254. doi: 10.1007/s00109-013-1090-5
   PubMed Web of Science ®Google Scholar
• Xiong J, Wang C, Chen H, et al. Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway. Int J Neurosci. 2014;124(8):609–620. doi: 10.3109/00207454.2013.865027
   PubMed Web of Science ®Google Scholar
• Jones RS, Minogue AM, Fitzpatrick O, et al. Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice. Neurobiol Aging. 2015;36(10):2716–2724. doi: 10.1016/j.neurobiolaging.2015.04.018
   PubMed Web of Science ®Google Scholar
• Choi M, Kim H, Yang EJ, et al. Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5xFAD mice, an animal model of Alzheimer’s disease. J Pharmacol Sci. 2020;143(4):290–299. doi: 10.1016/j.jphs.2020.05.009
   PubMed Web of Science ®Google Scholar
• Kheiri G, Dolatshahi M, Rahmani F, et al. Role of p38/MAPKs in Alzheimer’s disease: implications for amyloid beta toxicity targeted therapy. Rev Neurosci. 2019;30(1):9–30. doi: 10.1515/revneuro-2018-0008
   Web of Science ®Google Scholar
• Bachstetter AD, Xing B, de Almeida L, et al. Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation. 2011;8(1):79. doi: 10.1186/1742-2094-8-79
   PubMedGoogle Scholar
• Sun A, Liu M, Nguyen XV, et al. P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp Neurol. 2003;183(2):394–405. doi: 10.1016/S0014-4886(03)00180-8
   PubMed Web of Science ®Google Scholar
• Zhu X, Rottkamp CA, Boux H, et al. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000;59(10):880–888. doi: 10.1093/jnen/59.10.880
   PubMed Web of Science ®Google Scholar
• Perea JR, García E, Vallés-Saiz L, et al. P38 activation occurs mainly in microglia in the P301S tauopathy mouse model. Sci Rep. 2022;12(1):2130. doi: 10.1038/s41598-022-05980-8
   PubMed Web of Science ®Google Scholar
• Lin H, Dixon SG, Hu W, et al. P38 MAPK is a major regulator of amyloid beta-induced IL-6 expression in human microglia. Mol Neurobiol. 2022;59(9):5284–5298. doi: 10.1007/s12035-022-02909-0
   PubMed Web of Science ®Google Scholar
• Perea JR, Bolós M, Cuadros R, et al. P38 inhibition decreases tau toxicity in microglia and improves their phagocytic function. Mol Neurobiol. 2022;59(3):1632–1648. doi: 10.1007/s12035-021-02715-0
   PubMed Web of Science ®Google Scholar
• Son SH, Lee NR, Gee MS, et al. Chemical knockdown of phosphorylated p38 mitogen-activated protein kinase (MAPK) as a novel approach for the treatment of Alzheimer′s disease. ACS Cent Sci. 2023;9(3):417–426. doi: 10.1021/acscentsci.2c01369
   PubMed Web of Science ®Google Scholar
• Gee MS, Son SH, Jeon SH, et al. A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5xFAD mouse. Alzheimer’s Res Ther. 2020;12(1):45. doi: 10.1186/s13195-020-00617-2
   PubMed Web of Science ®Google Scholar
• Lauro C, Limatola C. Metabolic reprograming of microglia in the regulation of the innate inflammatory response. Front Immunol. 2020;11:493. doi: 10.3389/fimmu.2020.00493
   PubMed Web of Science ®Google Scholar
• Pan RY, He L, Zhang J, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer’s disease. Cell Metab. 2022;34(4):634–648.e6. doi: 10.1016/j.cmet.2022.02.013.
   PubMed Web of Science ®Google Scholar
• Hu Y, Cao K, Wang F, et al. Dual roles of hexokinase 2 in shaping microglial function by gating glycolytic flux and mitochondrial activity. Nat Metab. 2022;4(12):1756–1774. doi: 10.1038/s42255-022-00707-5
   PubMedGoogle Scholar
• Leng L, Yuan Z, Pan R, et al. Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance. Nat Metab. 2022;4(10):1287–1305. doi: 10.1038/s42255-022-00643-4
   PubMedGoogle Scholar
• Pan RY, Ma J, Kong XX, et al. Sodium rutin ameliorates Alzheimer’s disease-like pathology by enhancing microglial amyloid-β clearance. Sci Adv. 2020;5(2):eaau6328. doi: 10.1126/sciadv.aau6328
   Web of Science ®Google Scholar
• Esposito M, Sherr GL. Epigenetic modifications in Alzheimer’s neuropathology and therapeutics. Front Neurosci. 2019;13:476. doi: 10.3389/fnins.2019.00476
   PubMed Web of Science ®Google Scholar
• Bufill E, Ribosa-Nogué R, Blesa R. The therapeutic potential of epigenetic modifications in Alzheimer’s disease. Alzheimer’s Dis Drug Discov. 2020;9:151–164.
   Google Scholar
• Rao JS, Keleshian VL, Klein S, et al. Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients. Transl Psychiatry. 2012;2(7):e132. doi: 10.1038/tp.2012.55
   PubMedGoogle Scholar
• Wang X, Liu L, Jiang X, et al. Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease. Alzheimers Res Ther. 2023;15(1):164. doi: 10.1186/s13195-023-01311-9
   PubMed Web of Science ®Google Scholar
• Gao X, Chen Q, Yao H, et al. Epigenetics in Alzheimer’s disease. Front Aging Neurosci. 2022;14:911635. doi: 10.3389/fnagi.2022.911635
   PubMedGoogle Scholar
• Chuang DM, Leng Y, Marinova Z, et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32(11):591–601. doi: 10.1016/j.tins.2009.06.002
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng X, Li H, et al. Non-coding RNAs as novel regulators of neuroinflammation in Alzheimer’s disease. Front Immunol. 2022;13:908076. doi: 10.3389/fimmu.2022.908076
   PubMed Web of Science ®Google Scholar
• Freilich RW, Woodbury ME, Ikezu T, et al. Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia. PloS One. 2013;8(11):e79416. doi: 10.1371/journal.pone.0079416
   PubMed Web of Science ®Google Scholar
• Aloi MS, Prater KE, Sánchez REA, et al. Microglia specific deletion of mir-155 in Alzheimer’s disease mouse models reduces amyloid-β pathology but causes hyperexcitability and seizures. J Neuroinflammation. 2023;20(1):60. doi: 10.1186/s12974-023-02745-6
   PubMed Web of Science ®Google Scholar
• Qian Q, Zhang J, He FP, et al. Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer’s disease. FASEB J. 2019;33(3):4404–4417. doi: 10.1096/fj.201801846R
   PubMed Web of Science ®Google Scholar
• Zhao J, He Z, Wang J. MicroRNA-124: a key player in microglia-mediated inflammation in neurological diseases. Front Neurosci. 2021;15:771898. doi: 10.3389/fncel.2021.771898
   Web of Science ®Google Scholar
• Minter MR, Hinterleitner R, Meisel M, et al. Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPswe/PS1δE9 murine model of Alzheimer’s disease. Sci Rep. 2017;7(1):10411. doi: 10.1038/s41598-017-11047-w
   PubMed Web of Science ®Google Scholar
• Minter MR, Zhang C, Leone V, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci Rep. 2016;6(1):30028. doi: 10.1038/srep30028
   PubMed Web of Science ®Google Scholar
• Decandia D, Gelfo F, Landolfo E, et al. Dietary protection against cognitive impairment, neuroinflammation and oxidative stress in Alzheimer’s disease animal models of lipopolysaccharide-induced inflammation. Int J Mol Sci. 2023;24(6):5921. doi: 10.3390/ijms24065921
   PubMed Web of Science ®Google Scholar
• Abdelhamid M, Zhou C, Ohno K, et al. Probiotic bifidobacterium breve prevents memory impairment through the reduction of both amyloid-β production and microglia activation in APP knock-in mouse. J Alzheimer’s Dis. 2022;85(4):1555–1571. doi: 10.3233/JAD-215025
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Sugahara H, Shimada K, et al. Therapeutic potential of bifidobacterium breve strain a1 for preventing cognitive impairment in Alzheimer’s disease. Sci Rep. 2017;7(1):13510. doi: 10.1038/s41598-017-13368-2
   PubMed Web of Science ®Google Scholar
• Liu N, Yang D, Sun J, et al. Probiotic supplements are effective in people with cognitive impairment: a meta-analysis of randomized controlled trials. Nutr Rev. 2023;81(9):1091–1104. doi: 10.1093/nutrit/nuac113
   PubMed Web of Science ®Google Scholar
• Palasz E, Wilkaniec A, Stanaszek L, et al. Neurotrophic factors and glia crosstalk: possible role in pathobiology of neuroinflammation-related brain disorders. Int J Mol Sci. 2023;24(7):6321. doi: 10.3390/ijms24076321
   PubMed Web of Science ®Google Scholar
• Miranda M, Morici JF, Zanoni MB, et al. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13:363. doi: 10.3389/fncel.2019.00363
   PubMed Web of Science ®Google Scholar
• Zhang J, Rong P, Zhang L, et al. IL4-driven microglia modulate stress resilience through BDNF-dependent neurogenesis. Sci Adv. 2021;7(12):eabb9888. doi: 10.1126/sciadv.abb9888
   PubMed Web of Science ®Google Scholar
• Connor B, Young D, Yan Q, et al. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Mol Brain Res. 1997;49(1–2):71–81. doi: 10.1016/S0169-328X(97)00125-3
   PubMedGoogle Scholar
• Nagahara A, Merrill D, Coppola G, et al. Neuroprotective effects of BDNF in rodent and primate models of ad nih public access. Nat Med. 2009;15(3):331–337. doi: 10.1038/nm.1912
   PubMed Web of Science ®Google Scholar
• Jiao SS, Shen LL, Zhu C, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Transl Psychiatry. 2016;6(10):e907. doi: 10.1038/tp.2016.186
   PubMedGoogle Scholar
• Nagahara AH, Mateling M, Kovacs I, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013;33(39):15596–15602. doi: 10.1523/JNEUROSCI.5195-12.2013
   PubMed Web of Science ®Google Scholar
• Nigam SM, Xu S, Kritikou J, et al. Exercise and BDNF reduce Aβ production by enhancing α-secretase processing of APP. J Neurochem. 2017;142(2):286–296. doi: 10.1111/jnc.14034
   PubMed Web of Science ®Google Scholar
• Xie Y, Chen X, Li Y, et al. Transforming growth factor-β1 protects against LPC-induced cognitive deficit by attenuating pyroptosis of microglia via NF-κB/ERK1/2 pathways. J Neuroinflammation. 2022;19(1):194. doi: 10.1186/s12974-022-02557-0
   PubMed Web of Science ®Google Scholar
• Islam A, Choudhury ME, Kigami Y, et al. Sustained anti-inflammatory effects of TGF-β1 on microglia/macrophages. Biochimet Biophys Acta – Mol Basis Dis. 2018;1864(3):721–734. doi: 10.1016/j.bbadis.2017.12.022
   PubMed Web of Science ®Google Scholar
• Cao BB, Zhang XX, Du CY, et al. TGF-β1 provides neuroprotection via inhibition of microglial activation in 3-acetylpyridine-induced cerebellar ataxia model rats. Front Neurosci. 2020;14:187. doi: 10.3389/fnins.2020.00187
   PubMed Web of Science ®Google Scholar
• Chen X, Liu Z, Cao BB, et al. TGF-β1 neuroprotection via inhibition of microglial activation in a rat model of Parkinson’s disease. J Neuroimmune Pharmacol. 2017;12(3):433–446. doi: 10.1007/s11481-017-9732-y
   PubMed Web of Science ®Google Scholar
• Kapoor M, Chinnathambi S. TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized tau perspective. J Neuroinflammation. 2023;20(1):72. doi: 10.1186/s12974-023-02751-8
   PubMed Web of Science ®Google Scholar
• Shen WX, Chen JH, Lu JH, et al. TGF-β1 protection against Aβ1–42-induced neuroinflammation and neurodegeneration in rats. Int J Mol Sci. 2014;15(12):22092–22108. doi: 10.3390/ijms151222092
   PubMed Web of Science ®Google Scholar
• Podleśny-Drabiniok A, Marcora E, Goate AM. Microglial phagocytosis: a disease-associated process emerging from Alzheimer’s disease genetics. Trends Neurosci. 2020;43(12):965–979. doi: 10.1016/j.tins.2020.10.002
   PubMed Web of Science ®Google Scholar
• Gu Z, Cao H, Zuo C, et al. TFEB in Alzheimer’s disease: from molecular mechanisms to therapeutic implications. Neurobiol Dis. 2022;173:105855. doi: 10.1016/j.nbd.2022.105855
   PubMed Web of Science ®Google Scholar
• Mawuenyega KG. Decreased clearance of CNS amyloid-β in Alzheimer’s disease. Science. 2010;330(6012):1774. doi: 10.1126/science.1197623
   PubMed Web of Science ®Google Scholar
• Butler CA, Popescu AS, Kitchener EJA, et al. Microglial phagocytosis of neurons in neurodegeneration, and its regulation. J Neurochem. 2021;158(3):621–639. doi: 10.1111/jnc.15327
   PubMed Web of Science ®Google Scholar
• Targa H, Anastacio D. Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype? Transl Psychiatry. 2022;12:257. doi: 10.1038/s41398-022-02024-7
   PubMed Web of Science ®Google Scholar
• Novikova G, Kapoor M, Tcw J, et al. Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun. 2021;12(1):1610. doi: 10.1038/s41467-021-21823-y
   PubMed Web of Science ®Google Scholar
• Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54(4):412–436. doi: 10.1038/s41588-022-01024-z
   PubMed Web of Science ®Google Scholar
• Khani M, Gibbons E, Bras J, et al. Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease. Mol Neurodegener. 2022;17(1):3. doi: 10.1186/s13024-021-00505-9
   PubMed Web of Science ®Google Scholar
• Andrews SJ, Renton AE, Fulton-Howard B, et al. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. EBioMedicine. 2023;90:104511. doi: 10.1016/j.ebiom.2023.104511
   PubMed Web of Science ®Google Scholar
• Jiang T, Tan L, Chen Q, et al. Neurobiology of aging a rare coding variant in TREM2 increases risk for Alzheimer’s disease in han chinese. Neurobiol Aging. 2016;42:217.e1–3. doi: 10.1016/j.neurobiolaging.2016.02.023
   PubMed Web of Science ®Google Scholar
• Hickman S, Kingery N, Ohsumi T, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16(12):1896–1905. doi: 10.1038/nn.3554
   PubMed Web of Science ®Google Scholar
• Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):495–498. doi: 10.1016/j.bcp.2013.11.021
   PubMed Web of Science ®Google Scholar
• Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–675. doi: 10.1084/jem.20151948
   PubMed Web of Science ®Google Scholar
• Zhao N, Qiao W, Li F, et al. Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. J Exp Med. 2022;219(12):e20212479. doi: 10.1084/jem.20212479
   PubMed Web of Science ®Google Scholar
• Mazaheri F, Snaidero N, Kleinberger G, et al. TREM 2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18(7):1186–1198. doi: 10.15252/embr.201743922
   PubMed Web of Science ®Google Scholar
• Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22(2):191–204. doi: 10.1038/s41593-018-0296-9
   PubMed Web of Science ®Google Scholar
• Price BR, Sudduth TL, Weekman EM, et al. Therapeutic targeting of TREM2 by an activating antibody ameliorates amyloid‐beta deposition and improves cognition in the 5xFAD model of Alzheimer’s disease. Alzheimer’s Dement. 2019;17(1):238. doi: 10.1016/j.jalz.2019.06.4559
   Google Scholar
• van Lengerich B, Zhan L, Xia D, et al. A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models. Nat Neurosci. 2023;26(3):416–429.
   PubMed Web of Science ®Google Scholar
• Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12(4):e11227. doi: 10.15252/emmm.201911227
   PubMed Web of Science ®Google Scholar
• Boza A, Rocío S, Raquel R, et al. Galectin‑3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019;138(2):251–273. doi: 10.1007/s00401-019-02013-z
   PubMed Web of Science ®Google Scholar
• Thu VTA, Hoang TX, Kim JY. 1,25-dihydroxy vitamin DE3 facilitates the M2 polarization and β-amyloid uptake by human microglia in a TREM2-dependent manner. Biomed Res Int. 2023;3483411. doi: 10.1155/2023/3483411
   PubMed Web of Science ®Google Scholar
• Hollingworth P, Harold D, Sims R, et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43(5):429–435. doi: 10.1038/ng.803
   PubMed Web of Science ®Google Scholar
• Walker DG, Whetzel AM, Serrano G, et al. Association of CD33 polymorphism rs3865444 with Alzheimer’s disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging. 2015;36(2):571–582. doi: 10.1016/j.neurobiolaging.2014.09.023
   PubMed Web of Science ®Google Scholar
• Griciuc A, Federico AN, Natasan J, et al. Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet. 2020;29(17):2920–2935. doi: 10.1093/hmg/ddaa179
   PubMed Web of Science ®Google Scholar
• Wißfeld J, Nozaki I, Mathews M, et al. Deletion of Alzheimer’s disease-associated CD33 results in an inflammatory human microglia phenotype. Glia. 2021;69(6):1393–1412. doi: 10.1002/glia.23968
   PubMed Web of Science ®Google Scholar
• Aires V, Coulon-Bainier C, Pavlovic A, et al. CD22 blockage restores age-related impairments of microglia surveillance capacity. Front Immunol. 2021;12:684430. doi: 10.3389/fimmu.2021.684430
   PubMed Web of Science ®Google Scholar
• Pluvinage JV, Haney MS, Smith BAH, et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature. 2019;568(7751):187–192. doi: 10.1038/s41586-019-1088-4
   PubMed Web of Science ®Google Scholar
• Mishra S, Knupp A, Young JE, et al. Depletion of the AD risk gene Sorl1 causes endo-lysosomal dysfunction in human microglia. Alzheimer’s Dement. 2022;18(S4):e068943. doi: 10.1002/alz.068943
   Google Scholar
• Guo X, Tang P, Chen L, et al. Amyloid β-induced redistribution of transcriptional factor EB and lysosomal dysfunction in primary microglial cells. Front Aging Neurosci. 2017;9:228. doi: 10.3389/fnagi.2017.00228
   PubMed Web of Science ®Google Scholar
• Li T, Yin L, Kang X, et al. TFEB acetylation promotes lysosome biogenesis and ameliorates Alzheimer’s disease–relevant phenotypes in mice. J Biol Chem. 2022;298(12):102649. doi: 10.1016/j.jbc.2022.102649
   PubMed Web of Science ®Google Scholar
• Lo CH, Zeng J. Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases. Transl Neurodegener. 2023;12(1):29. doi: 10.1186/s40035-023-00362-0
   PubMed Web of Science ®Google Scholar
• Majumdar A, Capetillo-Zarate E, Cruz D, et al. Degradation of Alzheimer’s amyloid fibrils by microglia requires delivery of CIC-7 to lysosomes. Mol Biol Cell. 2011;22(10):1664–1676. doi: 10.1091/mbc.e10-09-0745
   PubMed Web of Science ®Google Scholar
• Lepiarz-Raba I, Gbadamosi I, Florea R, et al. Metabolic regulation of microglial phagocytosis: implications for Alzheimer’s disease therapeutics. Transl Neurodegener. 2023;12(1):48. doi: 10.1186/s40035-023-00382-w
   PubMed Web of Science ®Google Scholar
• McDonald CL, Hennessy E, Rubio-Araiz A, et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease. Brain Behav Immun. 2016;58:191–200. doi: 10.1016/j.bbi.2016.07.143
   PubMed Web of Science ®Google Scholar
• Rubio-Araiz A, Finucane OM, Keogh S, et al. Anti-TLR2 antibody triggers oxidative phosphorylation in microglia and increases phagocytosis of β-amyloid. J Neuroinflammation. 2018;15(1):247. doi: 10.1186/s12974-018-1281-7
   PubMedGoogle Scholar
• Hou Y, Wei Y, Lautrup S, et al. NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS – STING. Proc Natl Acad Sci, USA. 2021;118(37):e2011226118. doi: 10.1073/pnas.2011226118
   PubMed Web of Science ®Google Scholar
• Pedicone C, Fernandes S, Dungan OM, et al. Pan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis. J Cell Sci. 2020;133(5):jcs238030. doi: 10.1242/jcs.238030
   PubMed Web of Science ®Google Scholar
• Shi Q, Chang C, Saliba A, et al. Microglial mTOR activation upregulatesTREM2 and enhances β-amyloid plaque clearance in the 5xFAD Alzheimer’s disease model. J Neurosci. 2022;42(27):5294–5313.
   PubMed Web of Science ®Google Scholar
• Kana O, Brylinski M, Rouge B, et al. Elucidating the druggability of the human proteome with eFindsite. J Comput Aided Mol Des. 2019;33(5):509–519. doi: 10.1007/s10822-019-00197-w
   PubMed Web of Science ®Google Scholar
• Zhang MM, Guo MX, Zhang QP, et al. IL‑1R/C3aR signaling regulates synaptic pruning in the prefrontal cortex of depression. Cell Biosci. 2022;12(1):90. doi: 10.1186/s13578-022-00832-4
   PubMed Web of Science ®Google Scholar
• N’Songo A, Kanekiyo T, Bu G. LRP1 plays a major role in the amyloid-β clearance in microglia. Mol Neurodegener. 2013;8(S1):33. doi: 10.1186/1750-1326-8-S1-P33
   PubMedGoogle Scholar
• Yang L, Liu CC, Zheng H, et al. LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways. J Neuroinflammation. 2016;13(1):304. doi: 10.1186/s12974-016-0772-7
   PubMedGoogle Scholar
• Dobri AM, Dudău M, Enciu AM, et al. CD36 in Alzheimer’s disease: an overview of molecular mechanisms and therapeutic targeting. Neuroscience. 2021;453:301–311. doi: 10.1016/j.neuroscience.2020.11.003
   PubMed Web of Science ®Google Scholar
• Facci L, Barbierato M, Marinelli C, et al. Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1β release. Sci Rep. 2014;4(1):6824. doi: 10.1038/srep06824
   PubMedGoogle Scholar
• Zhong L, Sheng X, Wang W, et al. Article TREM2 receptor protects against complement- mediated synaptic loss by binding to complement C1q during neurodegeneration ll article TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity. 2023;56(8):1794–1808.e8. doi: 10.1016/j.immuni.2023.06.016
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang L, Yang J, et al. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer’s disease. Nat Commun. 2023;14(1):6670. doi: 10.1038/s41467-023-42505-x
   PubMed Web of Science ®Google Scholar
• Zhao P, Xu Y, Fan X, et al. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5xFAD mice. MAbs. 2022;14(1):2107971. doi: 10.1080/19420862.2022.2107971
   PubMed Web of Science ®Google Scholar
• Wu R, Li X, Xu P, et al. TREM2 protects against cerebral ischemia/reperfusion injury. Mol Brain. 2017;10(1):20. doi: 10.1186/s13041-017-0296-9
   PubMed Web of Science ®Google Scholar
• Zhao Y, Bhattacharjee S, Jones BM, et al. Regulation of TREM22 expression by an NF-kB-sensitive miRNA-34a. Neuroreport. 2013;24(6):318–323. doi: 10.1097/WNR.0b013e32835fb6b0
   PubMed Web of Science ®Google Scholar
• Song S, Yu L, Hasan MN, et al. Elevated microglial oxidative phosphorylation and phagocytosis stimulate post-stroke brain remodeling and cognitive function recovery in mice. Commun Biol. 2022;5(1):35. doi: 10.1038/s42003-021-02984-4
   PubMed Web of Science ®Google Scholar
• Li T, Li X, Huang X, et al. Mitochondriomics reveals the underlying neuroprotective mechanism of TrkB receptor agonist R13 in the 5×FAD mice. Neuropharmacology. 2022;204:108899. doi: 10.1016/j.neuropharm.2021.108899
   PubMed Web of Science ®Google Scholar
• Lloyd AF, Martinez-Muriana A, Hou P, et al. Deep proteomic analysis of human microglia and model systems reveal fundamental biological differences of in vitro and ex vivo cells. bioRxiv. 2022. doi: 10.1101/2022.07.07.498804
   Google Scholar
• Cadiz MP, Jensen TD, Sens JP, et al. Culture shock: microglial heterogeneity, activation, and disrupted single ‑ cell microglial networks in vitro. Mol Neurodegener. 2022;17(1):26. doi: 10.1186/s13024-022-00531-1
   PubMed Web of Science ®Google Scholar
• Mancuso R, Van Den Daele J, Fattorelli N, et al. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat Neurosci. 2019;22(12):2111–2116. doi: 10.1038/s41593-019-0525-x
   PubMed Web of Science ®Google Scholar
• Popova G, Soliman SS, Kim CN, et al. Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids. Cell Stem Cell. 2022;28(12):2153–2166.e6. doi: 10.1016/j.stem.2021.08.015
   Web of Science ®Google Scholar
• Paolicelli RC, Sierra A, Stevens B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron. 2022;110(21):3458–3483. doi: 10.1016/j.neuron.2022.10.020
   PubMed Web of Science ®Google Scholar
• Claire DA, Largeau B, Joao M, et al. Translocator protein-18 kda (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017;18(4):785. doi: 10.3390/ijms18040785
   PubMed Web of Science ®Google Scholar
• Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab—binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics. 2023;20(1):195–206. doi: 10.1007/s13311-022-01308-6
   PubMed Web of Science ®Google Scholar
• Budd Haeberlein S, Aisen P, Barkhof F, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer’s disease. J Prev Alzheimer’s Dis. 2022;2(9):197–210. doi: 10.14283/jpad.2022.30
   Google Scholar
• Cohen S, van Dyck CH, Gee M, et al. Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer’s disease. J prev Alzheimer’s dis. 2023;4(10):771–777. doi: 10.14283/jpad.2023.123
   Google Scholar
• Plowey ED, Bussiere T, Rajagovindan R, et al. Alzheimer disease neuropathology in a patient previously treated with Aducanumab. Acta Neuropathol. 2022;144(1):143–153. doi: 10.1007/s00401-022-02433-4
   PubMed Web of Science ®Google Scholar
• Cadiz MP, Gibson KA, Todd KT, et al. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024;221(2):e20231363. doi: 10.1084/jem.20231363
   PubMed Web of Science ®Google Scholar